MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 31 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $68,779,000 | -9.9% | 245,499 | -14.1% | 2.07% | +6.8% |
| Q1 2024 | $76,355,014 | +66.5% | 285,931 | +44.3% | 1.94% | +71.7% |
| Q4 2023 | $45,852,343 | +59.9% | 198,169 | +0.9% | 1.13% | +47.0% |
| Q3 2023 | $28,677,729 | -37.7% | 196,369 | -1.4% | 0.77% | -29.9% |
| Q2 2023 | $46,019,358 | -45.4% | 199,218 | -42.8% | 1.10% | -45.6% |
| Q1 2023 | $84,335,793 | -16.5% | 348,121 | 0.0% | 2.01% | -17.2% |
| Q4 2022 | $101,042,120 | +389.7% | 348,121 | +9.6% | 2.43% | +356.1% |
| Q3 2022 | $20,633,000 | -9.2% | 317,485 | 0.0% | 0.53% | -19.4% |
| Q2 2022 | $22,726,000 | -15.3% | 317,485 | +16.1% | 0.66% | -2.2% |
| Q1 2022 | $26,836,000 | +17.6% | 273,500 | +1.5% | 0.68% | +28.3% |
| Q4 2021 | $22,829,000 | +9.0% | 269,400 | +2.6% | 0.53% | +19.8% |
| Q3 2021 | $20,945,000 | -18.1% | 262,500 | 0.0% | 0.44% | -12.9% |
| Q2 2021 | $25,570,000 | -15.4% | 262,500 | +1.5% | 0.50% | -23.5% |
| Q1 2021 | $30,237,000 | +5.9% | 258,500 | +0.7% | 0.66% | +9.1% |
| Q4 2020 | $28,545,000 | -5.4% | 256,768 | +1.0% | 0.60% | -21.0% |
| Q3 2020 | $30,189,000 | +4.8% | 254,268 | 0.0% | 0.77% | -3.0% |
| Q2 2020 | $28,796,000 | +72.5% | 254,268 | +1.7% | 0.79% | +14.5% |
| Q1 2020 | $16,690,000 | -26.8% | 250,000 | -0.1% | 0.69% | -4.2% |
| Q4 2019 | $22,796,000 | -2.9% | 250,200 | -8.1% | 0.72% | -23.1% |
| Q3 2019 | $23,486,000 | -12.8% | 272,400 | +6.0% | 0.94% | -3.9% |
| Q2 2019 | $26,926,000 | -15.8% | 256,900 | +0.6% | 0.97% | -21.0% |
| Q1 2019 | $31,973,000 | +17.7% | 255,250 | +5.9% | 1.23% | -3.8% |
| Q4 2018 | $27,166,000 | -62.9% | 241,000 | -29.5% | 1.28% | -51.6% |
| Q3 2018 | $73,232,000 | -23.5% | 342,000 | -0.1% | 2.65% | -28.0% |
| Q2 2018 | $95,738,000 | +151.8% | 342,300 | +5.2% | 3.68% | +127.1% |
| Q1 2018 | $38,015,000 | +21.1% | 325,500 | -4.8% | 1.62% | +13.9% |
| Q4 2017 | $31,392,000 | +153.8% | 342,000 | +24.4% | 1.42% | +149.4% |
| Q3 2017 | $12,370,000 | +40.9% | 275,000 | -49.1% | 0.57% | +28.9% |
| Q2 2017 | $8,780,000 | +153.4% | 540,000 | +140.0% | 0.44% | +121.5% |
| Q1 2017 | $3,465,000 | +33.0% | 225,000 | +28.7% | 0.20% | +14.9% |
| Q4 2016 | $2,606,000 | +226.2% | 174,891 | +177.6% | 0.17% | +248.0% |
| Q3 2016 | $799,000 | – | 63,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 73,487 | $17,003,422 | 28.29% |
| Tao Capital Management LP | 130,529 | $30,202 | 27.63% |
| Paulson & Co. | 1,105,741 | $255,846,353 | 23.09% |
| AlpInvest Partners B.V. | 211,488 | $48,934,093 | 11.18% |
| Bain Capital Life Sciences Investors, LLC | 324,619 | $75,110,344 | 7.20% |
| Avoro Capital Advisors LLC | 1,888,888 | $437,050,905 | 6.04% |
| Propel Bio Management, LLC | 30,032 | $6,948,804 | 5.76% |
| Baker Brothers Advisors | 1,969,798 | $455,771,861 | 5.19% |
| Rosalind Advisors, Inc. | 25,000 | $5,784,500 | 4.76% |
| TCG Crossover Management, LLC | 179,917 | $41,629,195 | 4.62% |